HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

George Russell tapped CEO for company's North American division, following firm's recent acquisition of the Finesse and Aqua Net brands from Unilever, Lornamead Group announces June 7. Reporting to CEO of Lornamead Group Mike Jatania, Russell will oversee company's product development, manufacturing, distribution and marketing activities in North America, Central and South America, firm notes. Among his goals for the division, Russell notes he will guide the company in reinvesting in and reinvigorating the already well-established hair care brands, and will look for opportunities to acquire additional brands. Lornamead recently stated it hopes to build a $500 mil. personal care business in North America in the next three to five years (1"The Rose Sheet" May 15, 2006, In Brief)...

You may also be interested in...


UK company aims to build approximately $500 mil. personal care business in North America in the next three to five years, CEO Mike Jatania says, noting segment is now in excess of $100 mil. with the recent acquisition of Finesse and Aqua Net (1"The Rose Sheet" May 8, 2006, p. 6). In the next 60 days, Lornamead will consult with retailers, conduct focus groups and appoint public relations and advertising agencies to develop its marketing program for the brands, according to Jatania. In November, firm will launch new products under Yardley personal care brand, which was acquired from Procter & Gamble last year, exec adds. Company also markets Natural White teeth whitening products and Lypsyl lip balm...

Rising Costs, Price Pressure Usher In Uncertain Year Of The Rat In China

Once the world's factory, China has seen costs inch up while drug prices are being cut deeply by centralized procurement schemes. As uncertainties mount, companies need to focus on improving process and scale-up technology, suggested industry observers at a JPM panel discussion on innovation and market access challenges.

Biocon-Mylan's Plans For Broader US Fulphila Access, Glargine On Track

Biocon-Mylan press ahead with plans to broaden patient access in the US to biosimilar pegfilgrastim and are enthused with the initial uptake for their trastuzumab biosimilar ahead of more upcoming competition. A mid-2020 US launch for partnered insulin glargine is also on course.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts